Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + carboplatin + radiotherapy for cisplatin-unfit locally advanced head and neck squamous cell carcinoma
ACTRN12613000695707Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Apr 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Safety and feasibility. Started Apr 2008; status: completed.
02
Drugs
cetuximabcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ACTRN12613000695707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000695707.